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Introduction
Kidney transplantation is the preferred treatment for end-
stage renal disease (ESRD) because it is considerably less
expensive than dialysis on an overall basis and allows for
an almost normal life. One of the main reasons of graft
failure is delayed graft function (DGF), a form of acute
renal failure resulting in post-transplantation oliguria,
increased allograft immunogenicity and risk of acute
rejection episodes, and decreased long-term survival [1].
Roughly one-third of transplant patients receiving an
organ from a deceased donor develop DGF and have to
be treated by dialysis until the engrafted organ resumes
function. The hazard ratio for graft failure is almost twice
as high in recipients who experienced DGF when
compared with those without initial complications [2].
Factors which contribute to DGF can be divided into
donor-related and recipient-related factors. Donor-related
factors include donor age, diseases such as hypertension,
brain death-associated causes such as hemodynamic insta-
bility, massive cytokine release and vasopressor use. A
thorough discussion of donor and recipient factors con-
tributing to DGF was published by Schwarz et al. [3].
The fact that DGF is a rare exception in live kidney trans-
plantation suggests that donor factors rather than the
transplant procedure itself mainly contribute to DGF.
Next to the histopathological examination of renal
biopsies the determination of gene expression profiles in
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Summary
We recently showed in a randomized control trial that steroid pretreatment of
the deceased organ donor suppressed inflammation in the transplant organ but
did not reduce the rate or duration of delayed graft function (DGF). This study
sought to elucidate such of those factors that caused DGF in the steroid-treated
subjects. Genome-wide gene expression profiles were used from 20 steroid-
pretreated donor-organs and were analyzed on the level of regulatory protein–
protein interaction networks. Significance analysis of microarrays (SAM)
yielded 63 significantly down-regulated sequences associated with DGF that
could be functionally categorized according to Protein ANalysis THrough Evo-
lutionary Relationships ontologies into two main biologic processes: transport
(P < 0.001) and metabolism (P < 0.001). The identified genes suggest hypoxia
as the cause of DGF, which cannot be counterbalanced by steroid treatment.
Our data showed that molecular pathways affected by ischemia such as trans-
port and metabolism are associated with DGF. Potential interventional targeted
therapy based on these findings includes peroxisome proliferator-activated
receptor agonists or caspase inhibitors.
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donor organs poses an option to determine graft quality
and even predict transplant outcome to a certain extent
[4,5]. In a recent study from our group, we reported a
number of differentially regulated genes when comparing
donor organs from living and deceased donor organs.
Up-regulated genes in tissue samples from deceased
donors were mainly involved in inflammatory processes,
complement activation, apoptosis and cell adhesion [6].
Based on these findings, we initiated a randomized, dou-
ble-blinded, placebo-controlled trial to elucidate whether
pretreatment of deceased organ donors with corticosteroids
(1 g methylprednisolone) before organ retrieval will reduce
inflammation and subsequently the rate of DGF after
engraftment. One main finding of this study with 447 renal
allograft recipients was that steroid pretreatment caused a
reduction of inflammatory signatures in the donor kidney
as monitored on the level of gene expression profiles. How-
ever, neither the rate nor the duration of DGF was different
in the treatment and placebo group. We therefore hypothe-
size that additional pathways beyond those related to
inflammation are involved in the development of DGF.
Thus the analysis of the steroid treatment arm provides a
unique opportunity to investigate molecular mechanisms
other than inflammation which contribute to DGF.
Brain death is associated with rapid swings in blood
pressure, hypo- and hypertension, coagulopathies, pulmo-
nary changes, hypothermia and electrolyte aberrations
[7–9]. Therefore, donor brain death not only results in
increased inflammation but also leads to hypoperfusion
and hypoxia of the donor organ [10].
The main objective of this study was to elucidate
molecular causes of DGF that were not abolished by the
steroid donor pretreatment. Specifically, we compared the
molecular signature of kidney biopsies from steroid-trea-
ted donors with primary graft function in relation to kid-
neys with DGF. We sought to identify potential new
targets for intervention that ultimately may reduce the
current high rate of DGF.
Material and methods
Donor- and recipient characteristics
Out of the 238 recipients of steroid pretreated donor kid-
neys, we randomly identified 10 of 52 who developed
DGF and matched an equal number of primary graft kid-
neys. Matching variables of controls were cause of donor
death (stroke versus trauma) and caliper-matching of
donors’ last creatinine and donor age.
The rationale behind the sample size was that based on
previous data that 20 biopsies would be sufficient to
detect a more-than-twofold difference in the expression
of 30 predefined genes at an adjusted P-value of <0.05
using the Bonferroni–Holm method [6,11].
Trial design
Details on the multicenter trial may be found elsewhere
(http://www.controlled-trials.com/ISRCTN78828338 and
Kainz & Wilflingseder et al. [Abstract TTS Sydney 2008
#859, Annals of Internal Medicine submitted 2009] [12].
In brief, 269 donors stratified for age were equally ran-
domized in blocks of 4–1000 mg of corticosteroid or pla-
cebo injection 6 h before organ recovery. Before
transplantation, kidney wedge biopsies were obtained and
subjected to genomics analyses. The post-transplant clini-
cal course was monitored.
The study protocol was approved by the Institutional
Review Board (Ethical Committee of the Medical Univer-
sity of Vienna # EK-067/2005, to be found at http://
ohrp.cit.nih.gov/search/) and the EUROTRANSPLANT
kidney advisory committee (#6021KAC06) at each study
site and conducted according to IRB standards at each
institution. DGF was defined as the need for more than
one dialysis treatment within the first week after trans-
plantation or creatinine values above 3 mg/dl during the
first week after transplantation.
Laboratory procedures and biostatistical analyses
Donor kidney biopsy specimen, RNA isolation
and amplification
All organs were perfused with a histidine-tryptophan-
ketoglutarate (HTK) cold preservation solution at 4 C
during organ procurement [13]. The cold ischemic time
was not longer than 24 h. Wedge biopsies of each kidney
were taken under sterile conditions at the end of the cold
ischemic time right before transplantation. The biopsy
specimens were immediately submerged in RNAlater
(Ambion, Austin, TX, USA) and stored at 4 C.
Total RNA was isolated and purified using chloroform
and trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA
yield and quality was checked with the Agilent 2100 Bio-
analyzer and RNA6000 LabChip kit (Agilent, Palo Alto,
CA, USA). Stratagene Universal human reference RNA
was used as reference (Stratagene, La Jolla, CA, USA).
Two micrograms of isolated total RNA were amplified
using the RiboAmp RNA amplification kit (Arcturus,
Mountain View, CA, USA). The amplified RNA was
inspected on an ethidium bromide stained 1% agarose gel
and on the Agilent 2100 Bioanalyzer. For the 20 zero-
hour kidney biopsies, the RNA was of sufficient quality to
proceed with microarray analysis.
Microarray hybridization and scanning
Complementary DNA (cDNA) microarrays holding
41 421 (batch: SHEO) features were obtained from the
Stanford University Functional Genomics core facility. All
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microarray experiments were performed as described ear-
lier [14]. The detailed protocols are available at http://
genome-www.stanford.edu/. Using a type II experimental
setup, 1 lg of sample and standard Stratagene Universal
human reference aRNA were labeled with CyScribe cDNA
postlabeling kit (Amersham Pharmacia Biotech, Bucking-
hamshire, UK) in a two-step procedure.
Samples were loaded onto arrays and incubated for
18 h in a 65 C water bath. After three washing steps, the
fluorescence images of the hybridized microarrays were
examined using a GenePix 4100A scanner (Molecular
Devices, Sunnyvale, CA, USA). The genepix pro 6.0 soft-
ware (Molecular Devices, Sunnyvale, CA, USA) was used
to grid images and to calculate spot intensities. Arrays
were numbered according to the anonymous organ donor
ID, and were processed in random order. Image-, grid-
and data-files were submitted to the Stanford Microarray
Database (http://genome-www5.stanford.edu/MicroArray/
SMD/) and followed MIAME guidelines for arrays experi-
ments [15,16]. Raw data files as well as the MIAME
checklist are available at our laboratory webpage at http://
www.meduniwien.ac.at/nephrogene/data/DGF/.
Microarray data analysis
The microarray dataset consisted of 41 421 cDNA fea-
tures. 41 025 of those held a UniGene Cluster ID (27 442
unique genes), 396 were expressed sequence tags (ESTs)
not assigned to a UniGene Cluster. Mean sector and
printing plate anova R2-values of the microarray experi-
ments were on average 4.5 · 10)2 and 3.1 · 10)2 respec-
tively, suggesting no dependency of results on spatial
location or plate printing procedures. In a first prepro-
cessing step a quality filter was applied on the dataset by
considering only genes and ESTs with spot intensities of
at least 1.5-fold over background in either channel 1 or 2
of the microarray thus leaving 32 588 cDNA features in
the dataset. Only genes and ESTs with at least 80% of
valid entries were considered for successive analysis steps
thus further reducing the dataset to 24 624 cDNA fea-
tures. The remaining missing data points were substituted
applying a k-nearest-neighbor algorithm, where the num-
ber of neighbors, k, was set to 10 [17]. No correction for
a putative batch bias was necessary because only one
array batch was used in the whole analysis for all arrays.
We used the SAM methods as well as the Student’s t-test
in order to find differentially regulated genes (DEGs)
between patients experiencing DGF and the control group
with primary functioning (PF) grafts [18]. The P-value
threshold was set to <0.05 with fold-change values >2.
The number of permutations in the significance analysis
of microarrays (SAM) method was set to 20 000 and a
false discovery rate of 2.5% was selected. Differentially
expressed genes were hierarchically clustered and graphi-
cally represented using the MultiExperiment Viewer
developed at The Institute for Genomic Research [19].
The cosine correlation and complete linkage were used as
distance measure and linkage rule in the hierarchical clus-
ter algorithm respectively [19,20].
Functional data enrichment
Differentially regulated genes (DEGs) were furthermore
analyzed with respect to their molecular functions, associ-
ated biological processes, and cellular locations using gene
ontology terms (GO-Terms) as provided by the Gene
Ontology Consortium [21]. The SOURCE tool from the
Stanford Genomics Facility was used for linking
GO-Terms to the genes of interest [22]. Functional group-
ing of genes was based on GO-Terms, Protein ANalysis
THrough Evolutionary Relationships (PANTHER) ontolo-
gies, and information derived from the protein data retrie-
val system iHOP [23,24].
Regulatory network analysis
All identified DEGs were mapped on a molecular depen-
dency graph holding about 70 000 annotated human pro-
teins [25]. Each graph node codes for a particular
protein and edges between nodes encode pairwise depen-
dencies. Dependencies were computed based on protein–
protein interaction information, similarity in gene
expression, conjoint regulatory patterns on the level of
transcription factors and microRNAs, as well as assign-
ment to functional ontologies. Subnetworks holding at
least two DEGs were retrieved and further analyzed on a
functional level.
Statistical analysis
Continuous data were analyzed by Wilcoxon rank-sum
tests, categorical data by chi-squared tests or Fisher’s
exact tests when appropriate. A P-value <0.05 was consid-
ered statistically significant. For all analyses sas for Win-
dows 9.2 (The SAS Institute, Inc., Cary, NC, USA) was
used.
Results
Demographic data on transplant donors and recipients
are provided in Table 1.
Molecular signatures separating DGF from primary
function (PF) in steroid-treated donor organs
Using the SAM method, 63 transcripts could be identified
as significantly differentially regulated. Both gene lists are
provided in Tables S1 and S2 sorted by fold-change
values.
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In total, 147 features showed fold-change values >2 and
P-values smaller than 0.05 following a t-test. The majority
of features were suppressed with only 10 genes being
up-regulated in the DGF as compared with the PF group.
An expression profile-based clustering resulted in an
almost complete discrimination between DGF and PF
samples as given in Fig. 1.
Functional analysis
Thirty-nine out of the 63 transcripts (SAM, 41 unique
genes) and 84 out of the 135 down-regulated transcripts
(t-test, 91 unique genes) could be mapped to PANTHER
IDs. Significantly enriched or depleted biological processes
with at least two members are given in Table 2 (P-value
<0.05 given by a chi-squared test when comparing the
number of genes associated to the category with the total
number of genes belonging to this particular process).
Enriched processes mainly include genes involved in trans-
port and metabolism. DGF-associated down-regulated
genes include many transcripts encoding solute carriers
(ion, amino acid and glucose transporters) in the plasma
membrane and other transporters in the cytoplasma and
extracellular space. Prominent members are the organic
anion transporter (SLC22A8), neutral amino acid trans-
porter (SLC6A19), the sodium/glucose cotransporter
(SLC5A12), lipocalin 2 (LCN2), and apolipoprotein D
(APOD). Proteins involved in metabolism, including lipid,
fatty acid, and steroid metabolism, were predominantly
down-regulated in DGF samples. Depleted processes are
nucleoside and protein metabolism, mRNA transcription
and intracellular protein traffic. Up-regulated transcripts
(t-test, nine unique genes) were mainly associated with
blood clotting as well as immunity and defense.
Interactome analysis
We retrieved in total seven networks holding at least two
of the differentially regulated genes (Fig. 2). Members of
network cluster 1 holding 13 proteins are mainly involved
in blood clotting with fibrinogen gamma (FGG), fibrino-
gen alpha (FGA), and the frizzled homology 8 being
up-regulated in patient samples experiencing DGF.
Hypoxia and an older donor age might lead to the activa-
tion of fibrotic pathways which contribute to DGF. The
central protein of network cluster two is the suppressor
of cytokine signalling 3 (SOCS3) that shows higher
expression values in the group of patients with DGF post-
transplant. The other network clusters contain mainly
down-regulated genes with members of cluster 6 being
involved in steroid metabolism and members of clusters 4
and 7 being involved in lipid and fatty acid metabolism
(Fig. 2).
Discussion
In this study, we elucidated molecular mechanisms associ-
ated with DGF after renal transplantation in zero-hour
Table 1. Demographic data of transplant donors and recipients stratified by treatment assignment. Continuous data are provided as median
(first, third quartile), categorical data are shown as counts.
PF group DGF group P-value
No. donors 16 na
No. donor organs 10 10 na
Donor age (years) 52.5 (45.0, 58.0) 62.5 (55.0, 72.0) 0.045
Donor gender (female/male) 4/6 7/3 0.370*
Last creatinine of donor (mg/dl) 1.00 (0.71, 1.20) 0.70 (0.60, 1.00) 0.254
Vasopressors used (n/year) 2/8 0/10 0.136
Multiorgan donors (n/year) 7/3 8/2 1.000*
Cause of death (trauma/intracranial
hemorrhage/cardiac arrest/else)
1/8/1/0 0/9/0/1 0.383
No. recipients 10 10 na
Recipient age (years) 57.3 (51.6, 62.2) 59.1 (46.3, 67.1) 0.734
Recipient gender (female/male) 3/7 3/7 1.000
Transplant number (1/2) 9/1 9/1 1.000*
Cold ischemic time (h) 9.9 (7.0, 15.0) 12.7 (10.3, 4.4) 0.308
PRA latest (%) 0.0 (0.0, 2.0) 0.0 (0.0, 2.0) 1.000
Sum of HLA mismatches (0/1/2/3/4/5/6) 0/1/4/1/1/0/0 0/0/1/3/1/5/0 0.076*
No. dialysis treatment (0/1/2/3/4) 10/0/0/0/0 3/5/0/1/1 0.003*
Immunosuppression (CNI/else) 8/2 9/1 1.000*
Induction therapy (none/antiCD25/ATG) 6/4/0 7/3/0 0.639
na, not applicable.
*Fisher’s exact test.
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donor kidney biopsies pretreated with corticosteroids.
Based on our findings, poor initial function can be
explained by a partial shutdown of metabolism and trans-
port activity on a molecular level.
One possible explanation of reduced transport and
metabolism is hypoxia. In the absence of oxygen, severe
energy depletion, i.e. less production of ATP and subse-
quent activation of number of critical alterations in
metabolism, occurs [26]. The effects of limited oxygen
supply are aggravated by the higher demand associated
with the high tubular oxygen consumption necessary for
solute exchange [27] and the high rate of aerobic glycoly-
sis [28]. Hypoxia is also a profibrogenic stimulus for
tubular cells, interstitial fibroblasts, and renal microvascu-
lar endothelial cells. Hypoxia can also activate fibroblasts
and change the extracellular matrix metabolism of resi-
dent renal cells [29,30] and has been shown to play a role
in the progression of chronic kidney disease [31]. There-
fore, the use of effective preservation solutions and reduc-
tion of cold ischemia times may improve kidney function
after transplantation [32].
The down-regulation of many transporters is probably
caused by less oxygen supply and subsequent energy
depletion. The solute carrier family 4, sodium bicarbonate
cotransporter, member 4 (SLC4A4) built a small cluster
with the carbonic anhydrase IV (CA4) and is involved in
the regulation of bicarbonate secretion and absorption
and intracellular pH suggesting tubular acidosis (Fig. 2).
Protein–protein interactions of transporters in the molec-
ular dependency graph are rare suggesting that these
pathways are under-represented in the interactome analy-
sis.
Lipid metabolism, fatty acid metabolism and steroid
metabolism are down-regulated in DGF samples and are
the most enriched functional categories next to transport
function (Fig. 2, network clusters 4, 6, 7). Although the
hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD),
the sulfotransferase family, cytosolic, 1C, member 2
(SULT1C2), and the three glucuronosyltransferase 2
family polypeptides UGT2B15, UGT2B4, UGT2B7 are
members of the steroid metabolism, they cannot be
linked directly to methylprednisolone treatment. Another
Figure 1 Dendrogram derived by unsupervised hierarchical clustering of gene expression profiles dichotomizing delayed graft function (DGF)
group (grey bar) from primary function (PF) (black bar), all received steroid pretreatment. Grey spots indicate up-regulated or down-regulated tran-
scripts relative to the reference RNA used. The differentially regulated genes associated with DGF could be categorized according to GO-terms
mainly into transport and metabolism.
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prominent gene, the suppressor of cytokine signaling 3
(SOCS3), belongs to a family of negative-feedback regula-
tors of cytokine signaling. This regulator is induced by its
corresponding cytokines leading to the subsequent shut-
down of the respective signaling cascade [33]. SOCS3 is
involved in the JAK/STAT-dependent cytokine signaling
pathways and is linked to the down-regulated prolactin
receptor. On the other side, SOCS3 is linked over IRS2
(insulin receptor substrate 2) to the down-regulated insu-
lin receptor (Fig. 2, cluster 2).
Reduced transport activity and metabolism indicating
poorer quality of renal grafts was also reported by other
trancriptomics studies of donor kidney biopsies develop-
ing DGF [6,34,35]. Approximately one-third of reported
down-regulated genes by Mueller et al. were also identi-
fied in our study, thus strengthening the validity of
obtained results. The common theme of inflammation
and immune response in the context of DGF was delin-
eated in all three studies. The suppression of inflamma-
tion with corticosteroids in our study led to the
identification of novel molecular mechanisms besides
inflammation and complement activation associated with
the development of DGF, namely limited transport capa-
bilities and decreased metabolic activity of the renal
organ. However, one cluster in the dependency graph
with the down-regulated major histocompatibility com-
plex, class II, DR beta 3 (HLA-DRB1) and the up-regu-
lated CD3d molecule, delta (CD3-TCR complex) (CD3D)
belongs to immunity response.
A fair number of induced genes in DGF samples could
be linked to blood clotting with fibrinogen gamma and
fibrinogen alpha being two prominent members. This
Table 2. Functional classification of DEGs using PANTHER ontologies: Enriched or depleted biological processes Separating DGF and PF as derived
on the level of differential gene expression by t-test and SAM. Categories are ranked by the P-value (comparison of expected number of genes
and observed number of genes in each biological process) indicating the relevance of a particular process.
Biological process
t-test (n = 84) SAM (n = 39)
No. genes P-value No. genes P-value
DEGs down-regulated in DGF enriched processes
Transport 20 <0.001 8 0.001
Lipid, fatty acid and steroid metabolism 12 <0.001 5 0.006
Amino acid metabolism 7 <0.001 2 0.049
Steroid hormone metabolism 4 <0.001 2 0.002
Steroid metabolism 6 <0.001 3 0.003
Ion transport 9 <0.001 – –
Coenzyme and prosthetic group metabolism 5 <0.001 3 0.003
Amino acid transport 3 0.001 – –
Carbohydrate metabolism 8 0.001 – –
Fatty acid metabolism 4 0.004 – –
Other amino acid metabolism 2 0.005 – –
Cation transport 6 0.005 – –
Electron transport 4 0.010 – –
Vitamin/cofactor transport 2 0.011 – –
Other polysaccharide metabolism 3 0.012 – –
Cell adhesion 6 0.017 – –
Homeostasis 3 0.028 – –
Extracellular transport and import 2 0.028 – –
Anion transport 2 0.034 – –
Sulfur metabolism 2 0.035 – –
Proteolysis 7 0.036 – –
Other developmental process 2 0.042 – –
Depleted processes
Nucleoside, nucleotide and nucleic acid metabolism 5 0.042 – –
Intracellular protein traffic 0 0.043 – –
mRNA transcription 2 0.047 – –
DEGs up-regulated in DGF-enriched processes t-test (n = 9) SAM (n = 0)
Blood circulation and gas exchange 2 <0.001 – –
Blood clotting 2 <0.001 – –
Immunity and defense 3 0.009 – –
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might in part be explained by the advanced age of the
donors in the DGF group. Donor age is a well known risk
factor of DGF but not all grafts from old donors have
necessarily poor graft function. Determination of the graft
quality based on demographic/clinical and molecular risk
factors probably provides a much better forecast model
[4]. Especially the shortage of donor organs makes an
expansion of donor criteria to include older and non-
heart-beating donors necessary with the risk of higher
rates of DGF. Therefore a better understanding of molec-
ular mechanisms leading to DGF is of great interest and
new strategies and better donor management is of great
importance for the prevention of this disease.
A limitation of this study is probably the use of cDNA
arrays which cannot discriminate between different splice
variants in the measurement of expression levels. None-
theless, we could identify genes mainly involved in trans-
port and lipid, glucose metabolism associated with DGF
in renal transplants.
Based on these results, it can be hypothesized that the
activation of lipid and glucose metabolism may prevent
the graft from developing acute renal failure. One possible
treatment strategy is the administration with peroxisome
proliferator-activated receptor (PPAR) agonists. The
PPARs are ligand-activated transcription factors that con-
trol lipid and glucose metabolism. Activation of PPARs
negatively regulates the expression of genes induced by
cerebral ischemia/reperfusion injury and was shown to
prevent post-ischemic inflammation and neuronal dam-
age in several in vitro and in vivo models [36].
Another possible strategy to revert the effects of
hypoxia is the treatment with caspase inhibitors. The
administration of caspase inhibitors in vivo was demon-
strated to protect against cell death in animal models of
ischemic acute renal failure [37]. The pancaspase inhibi-
tor Q-VD-OPH prevents the rise in caspase activity and
apoptosis [38]. Therefore PPAR-agonists and caspase
inhibitors may be adopted in the donor pretreatment to
prevent ischemic/reperfusion injury in the kidney. Donor
pretreatment has great advantages for the recipient
because improved long-term survival could thus be
achieved cost-efficiently and without great effort or side-
effects.
In summary, our analyses provide novel insight into
the biological processes that are associated with postis-
chemic DGF. Based on our findings prospective trials
with targeted therapy, including PPAR-agonists or caspase
inhibitors, may be designed to elucidate the causal infer-
ence of these risk markers of DGF.
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online version of this article:
Table S1. Sixty-three differentially regulated transcripts
computed with the significance analysis of microarrays
(SAM) method sorted by fold-change values. The number
Figure 2 Seven identified networks with at least two differentially regulated genes between delayed graft function (DGF) and primary function
(PF) samples. Dark grey nodes depict up-regulated genes in DGF samples whereas light grey nodes depict down-regulated genes. Differentially
expressed proteins showed a high connectivity in these networks, thus indicating concerted interaction and relevance in the development of DGF.
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of permutations in the SAM method was set to 20 000
and a false discovery rate of 2.5% was selected.
Table S2. One hundred and forty-seven differentially
regulated transcripts computed with the Student’s t-test
sorted by fold-change values. The P-value threshold was
set to <0.05 with fold-change values >2.
Please note: Wiley-Blackwell are not responsible for the
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